Alzheimer's disease (AD) is the most common cause of dementia worldwide. The etiology is
multifactorial, and pathophysiology of the disease is complex. Data indicate an exponential …

Alzheimer's disease (AD) is a neurodegenerative disorder and is identified as the most
common cause for dementia. Despite huge global economic burden and the impact on the …

Alzheimer's disease (AD) is a devastating neurological disorder that affects more than 37
million people worldwide1. The economic burden of AD is massive; in the United States …

Given the acknowledged lack of success in Alzheimer's disease (AD) drug development
over the past two decades, the objective of this review was to derive key insights from the …

Alzheimer's disease is a devastating neurological disorder that affects more than 37 million
people worldwide. The economic burden of Alzheimer's disease is massive; in the United …

Alzheimer's disease (AD) was first described a little more than 100 years ago. It is the most
common cause of dementia with an estimated prevalence of 30 million people worldwide, a …

Alzheimer's disease (AD) and its related dementia has shown an alarming rise in the global
population. Although considerable efforts have been made to develop effective therapeutic …

Alzheimer's disease (AD) has been a global concern for years due to its severe implications
that affects the quality of life of the patients. The available line of therapy for treating …

Aducanumab (aducanumab-avwa; Aduhelm™) is a human, immunoglobulin gamma 1
(IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of …

Alzheimer's disease (AD) is the sixth-leading reason of fatality and is 70% present in all
cases of dementia. The global burden of AD is expected to accelerate from 26.6 million …